PQRI Case Study (2): Functional Equivalence for Equipment Replacements - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PQRI Case Study (2): Functional Equivalence for Equipment Replacements
The second in a series of eight case studies from the Product Quality Research Institute focuses on functional equivalence for equipment.


Pharmaceutical Technology
Volume 35, Issue 8, pp. 72-75

Pharmaceutical manufacturers have an obligation to ensure that their manufacturing equipment is properly designed, installed, tested, operated, and maintained throughout their service lifetimes. During these service lifetimes, manufacturing equipment will likely require both preventive and corrective maintenance activities that may involve the replacement of parts within the systems. Parts replacements must be performed under the appropriate change controls to ensure that manufacturing equipment remains in a validated state with respect to installation, operation, and performance. Change-control considerations are greatly facilitated when replacement parts are exactly identical to the original parts. However, it is not uncommon for pharmaceutical manufacturers to resort to procuring and installing replacement parts that are not identical to the original parts due to changes affected by parts suppliers (e.g., product redesigns, discontinuations). In these instances, a risk-management approach may be used to systematically assess whether replacement parts are functionally equivalent (i.e., like-for-like) with original parts to ensure proper change control while also preventing unnecessary revalidation activities.

This case study on functional equivalence for equipment replacements is the second of eight in a series put together by the Product Quality Research Institute Manufacturing Technical Committee (PQRI–MTC) risk-management working group. The series is meant to advance the understanding and application of the International Conference on Harmonization (ICH) Q9 Quality Risk Management guideline by providing actual examples of risk-management assessments used by the bio/pharmceutical industry. The introductory article explaining the history and structure of the series, as well as the first case study, on defining design space, appeared in the July 2011 issue of Pharmaceutical Technology (1).

In this case study, a risk-management approach was taken by the firm to identify the following:

  • Risks associated with equipment-parts changes that might adversely impact the validated state of manufacturing equipment
  • Risks associated with the process of determining whether original and replacement parts are functionally equivalent
  • Proper roles and responsibilities of the functional areas involved in the process of determining whether original and replacement parts are functionally equivalent.

The outputs of the risk-management approach used by the firm included a generic, robust, and repeatable process for performing functional-equivalence assessments as well as defining organizational roles and responsibilities supporting the process.

Risk question and risk-assessment method

The risk question developed for the subject case study was: What process and associated functional area roles and responsibilities are required in order to assess whether replacement parts are functionally equivalent with original parts in order to ensure proper manufacturing-equipment change control while also preventing unnecessary revalidation activities?

The firm elected to craft one risk assessment for the overall (generic) functional-equivalence assessment process to achieve two objectives:

  • Identify potential gaps, inconsistencies, and redundancies within the process that had historically been used for replacement-parts functional equivalence determinations
  • Identify new or improved activities that would lead to robust, efficient, and consistent functional-equivalence assessments moving forward.

To support selection of a risk-assessment method, the team examined the above risk question and identified the core activities supporting the historical functional-equivalence assessment process. Core activities examined included the equipment change-control process and the maintenance-systems inventory process-control flow. The team noted the following observations:

  • The functional-equivalence assessment process was historically dependent upon human judgment, expertise, and experience
  • Process risks (e.g., potential breakdowns of the process) were qualitative in nature and difficult to quantify with specificity.

Given these observations, the risk-assessment team selected Fault Tree Analysis (FTA) as its risk-assessment method because it is well suited for analysis of qualitative fault conditions that may be related to human performance factors.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here